Abstract
HISTOPATHOLOGIC STAGING is used to predict which colorectal cancer patients are at sufficient risk for micrometastatic disease to justify the use of adjuvant therapy. However, current staging fails to take into account the cellular and molecular markers of high-risk disease. The markers described in this review have evolved from our current molecular model of colorectal cancer development. We hope they will enhance our ability to more accurately identify patients at risk and more effectively treat colorectal cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 331-335 |
| Number of pages | 5 |
| Journal | Cancer Bulletin |
| Volume | 46 |
| Issue number | 4 |
| State | Published - 1994 |
ASJC Scopus subject areas
- Cancer Research